The prospects of shifting clinical data requirements from premarket to postmarket to support cochlear implant modifications for pediatric patients will discussed at an upcoming FDA Ear, Nose and Throat Devices Panel meeting.
The panel will meet April 30 and May 1 first to recommend risk-classification categories for five types of hearing devices and, on the second day, consider the